ABSTRACT
Deramciclane, a camphor derivative, is a novel anxiolytic agent with a unique mechanism of action. It acts as a potent and specific antagonist at serotonin 5-HT2A/2C receptors, and exhibits anxiolytic efficacy in animal models. The aim of this double-blind, placebo-controlled, parallel-group study was to evaluate the efficacy, safety, and tolerability of a range of doses of deramciclane in patients with generalized anxiety disorder (GAD). Adult patients with a diagnosis of GAD (DSM-IV) and a Hamilton Anxiety Rating Scale (HAM-A) total score >or=18; a score >or=2 for the HAM-A items 'Anxious Mood' and 'Tension'; a score >or=4 on the Clinical Global Impression of Severity of Illness (CGI-S) Scale; and a score Subject(s)
Anti-Anxiety Agents/therapeutic use
, Anxiety Disorders/drug therapy
, Camphanes/therapeutic use
, Adolescent
, Adult
, Aged
, Anti-Anxiety Agents/administration & dosage
, Camphanes/administration & dosage
, Double-Blind Method
, Female
, Humans
, Male
, Middle Aged
, Psychiatric Status Rating Scales
, Recurrence
